impact of this on the treatment of asthma. METHODS: Our submission to NICE reviewing the relative value of alternative products, utilised a cost-minimisation approach, recognising that there was little evidence of clinical differentiation between the ICS. RESULTS: It was estimated that a total switch to QVAR upon withdrawal of CFC based BDP, would result in only a modest 6% increase in costs to the NHS, but could result in overall cost savings if it were substituted for more costly ICS alternatives, such as fluticasone propionate or budesonide. CON-CLUSION: There remain concerns that NICE may overlook the current political and socioeconomic imperatives and provide Guidance that does not consider appropriate BDP dosing or recognise that the environment will change over its period of jurisdiction. OBJECTIVES: Frequent use of short-acting beta agonists (SABA) inhalers, along with insufficient use of concurrent steroid inhalers, is often the cause of suboptimal management of the disease. The aim of the study is to identify the heavy purchasers of SABA and improve the management of there disease. METHODS: All Maccabi Healthcare Services (MHS) patients in two areas in the Shfela district who consumed al least 4 SABA inhalers during 2005 were identified using MHS's computerized database. The patients' primary care physicians (PCP) were briefed with the findings and where presented the current evidence based medicine (EBM) clinical guidelines for proper asthma treatment in a group meetings with pulmonologist. Later the PCP attend to two days workshop dealing with appropriate asthma treatment, patient's adherence and practicing clinical scenarios with professional actors. A 3rd meeting included case presentations and further discussions with a pulomonologist. A control group consisted of patients of PCPs in other areas in the Shfela district which didn't participate in the study. RESULTS: One hundred six patients were in the intervention group. 85 required more then 2 SABA inhalers in the first 6 month after intervention (decrease of 20%). In the control group there was a 4% increase in patients using more than 2 SABA inhalers during the same period (185 to 193). CONCLUSION: We have observed a significant improvement in SABA consumption. This improvement applies that educational efforts on applying EBM clinical guidelines for proper asthma treatment and providing simple tools for dealing with patients' adherence, can improve management and control of asthma and can lower asthma's treatment expenses. We suggest similar interventions on other chronic diseases.
PAA15 EFFECT OF IMMUNOTHERAPY ON DRUG USE AND COST IN RAGWEED POLLEN ALLERGIC DISEASE IN LOMBARDIA
Ortolani C 1 , Berto P 2 , Frati F 3 , Aiello A 2 , Bertani G 4 1 Istituto Allergologico Lombardo OnLus, Cesano Boscone, Italy, 2 pbe consulting, Verona, Italy, 3 Stallergenes Italy, Milano, Italy, 4 General Health Directorate-Regione Lombardia, Milano, Italy OBJECTIVES: Clinical efficacy and cost-effectiveness of immunotherapy in allergic disease caused by various allergens is demonstrated by several published studies, but economic value is still far from being appreciated by local decision makers. Scope of this work was to provide the Regional decision makers with real world information on the use and impact of immunotherapy in terms of efficacy on symptoms, use and cost of drugs in patients affected by rhinoconjunctivitis (RC) with or without asthma (A), caused by ragweed seasonal allergy. METHODS: Observational study, of precoseasonal sublingual (SLIT) or preseasonal subcutaneous immunotherapy (SCIT) versus non-immunotherapy (NSIT). Patients enrolled by a network of specialist centres from Lombardia, were randomly assigned to one of the study groups and were allowed to take any additional medication needed to control RC and A symptoms; effectiveness was measured as global symptom score rated by the patient on a VAS at last visit; drug consumption was measured as days of medication recorded by the patient on a weekly diary card during the peak season; drug cost was calculated by applying Italian NHS prices. RESULTS: For the first year of immunotherapy, 163 adults were analyzed (SLIT N = 67 M = 48%, age 39+/-9.1; SLIT N = 34 M = 62%, age 41+/-8.1; NSIT N = 62 M = 53%, age 36+/-9.2); 25% of SLIT patients were affected by A as compared to 47% of SCIT and 37% of NSIT patients; 55% of SLIT patients were treated with high dose SLIT. The mean number of drug treatment days/patient was lower for SLIT patients 26.15+/-30.1 vs. NSIT 58.7+/-43.4 (p < 0.0001) and for SCIT patients 33.0+/-45.7 vs NSIT 58.7+/-43.4 (p < 0.05); similarly the mean total cost/ patient of drug treatment was lower with SLIT €28.19 vs SCIT €33.9 and NSIT €59.2. CONCLUSION: SLIT and SCIT can effectively reduce use and cost of drug treatment in adults affected by rhinoconjunctivitis with/without asthma caused by ragweed in Lombardia.
PAA16 A RETROSPECTIVE STUDY COMPARING TREATMENT PATTERNS, OUTCOMES, AND RESOURCE USE BETWEEN TWO FIXED COMBINATIONS OF INHALED CORTICOSTEROIDS AND LONG-ACTING B2-AGONIST (ICS/LABA) IN ASTHMATIC PATIENTS IN GERMANY
Aballéa S 1 , Cure S 1 ,Vogelmeier C 2 , Wirén A 3 1 i3 Innovus, Uxbridge, Middlesex, UK, 2 University of Marburg, Marburg, Germany, 3 AstraZeneca, Lund, Sweden OBJECTIVES: Formoterol/budesonide (BUD/FORM) and salmeterol/fluticasone propionate (SAL/FLU) have been shown to be effective in the treatment of asthma. This retrospective, observational study compared characteristics of patients initiating treatment with BUD/FORM or SAL/FLU in routine clinical practice, subsequent treatment outcomes and resource utilisation. METHODS: A cohort of German patients diagnosed with asthma, followed from 12 months before to 12 months after treatment initiation with BUD/FORM or SAL/FLU, was extracted from a longitudinal, primary care database of records collected from June 2000 to June 2006. The primary outcome was the proportion of successfully treated patients defined according to utilisation of short-acting beta-agonists (SABA) and switches or addition of controller medications during the postindex year. Secondary outcomes included resource utilisation and acute exacerbations, defined as at least one oral corticosteroid (OCS) prescription and/or hospitalisation related to asthma. Regression models were used to adjust for patient characteristics, including treatment history. RESULTS: The BUD/FORM and SAL/FLU groups included 1,456 and 982 patients, respectively. Prior to treatment initiation, patients in the BUD/FORM group received less asthma-related OCS prescriptions (mean difference: -0.049, p = 0.0328) but utilisation of SABA, ICS and LABA was similar. In the year following treatment initiation, patients initiating on BUD/FORM had a greater probability of treatment success (OR = 1.54, p = 0.0001), fewer acute exacerbations (-40.2%, p = 0.0007) and fewer physician visits (-4.4%, p = 0.0259), than those on SAL/FLU, after controlling for baseline characteristics. The BUD/FORM patients were less likely to switch to an alternative ICS + LABA combination (OR = 0.58, p = 0.0067). Numbers of hospitalisations, referrals and work absences did not differ between groups. CONCLUSION: BUD/ FORM was associated with a lower probability of treatment switches, fewer acute exacerbations, and with similar or lower resource utilisation compared with SAL/FLU. Although the groups appeared well matched at treatment initiation, these results should be interpreted with caution given the observational nature of this study.
PAA17 PHYSICIAN ADHERENCE TO NATIONAL ASTHMA PRESCRIBING GUIDELINES: EVIDENCE FROM U.S. OUTPATIENT VISITS
Navaratnam P 1 , Jayawant SS 2 , Pedersen CA 2 , Balkrishnan R 2 1 The Ohio State University, Columbus, OH, USA, 2 The Ohio State University College of Pharmacy, Columbus, OH, USA OBJECTIVES: EPR-2 guidelines were developed to improve medication prescribing for patients with persistent asthma and to control acute exacerbations of asthma. In addition these guidelines also encourage physician provided asthma education. Little is known about prescribing adherence to EPR-2 guidelines. This study examined physician adherence to EPR-2 asthma medication prescribing guidelines and determine patient and physician factors associated with prescribing of asthma medications. METHODS: This study was a cross-sectional retrospective analysis of complex NAMCS physician visit survey data from 1998 through 2004. Data were extracted on all patient s with an ICD-9 code for asthma (493.XX) and reason for visit as 'asthma'. Unit of analysis was individual patient visit. Dependent variables in analyses were specific type of drug class. Independent variables were various patient and physician factors. Logistic regression analysis was used to assess study objectives. RESULTS: Asthma patients in 2002 were 3.3 times more likely to be prescribed controller medications compared in 1998. Findings in 2004 were not significant. Elderly patients were 54% as likely to receive controller medication compared to the 35-64 year age group. Patients other than whites or African Americans are 40% as likely to receive controller asthma medication compared to whites. Physicians were 6.3 times more likely to prescribe long acting beta agonists compared to 1998. Physicians without ownership stake in their practice were 1.9 times more likely to provide asthma education to their patients compared to those who owned their practice. CONCLUSION: This study using US outpatient setting data provides evidence that physician prescribing of asthma pharmacotherapy in the US does not adequately comply with EPR-2 treatment guidelines.
PAA18 USING CLAIMS DATA TO MODEL THE BUDGETARY IMPACT OF A NEW TREATMENT FOR RHINITIS
Pandya A 1 , Rubin JL 1 , Henk HJ 2 , Borah B 2 , McGarry L 1 1 i3 Innovus, Medford, MA, USA, 2 i3 Innovus, Eden Prairie, MN, USA OBJECTIVES: Medical care costs for rhinitis are primarily driven by patient care-seeking behavior and physician prescribing patterns, which may evolve over time. Estimating a model of real-world rhinitis treatment from clinical trial data is not feasible due to short trial durations and protocol-driven care. Therefore, we used U.S. health care claims data to model rhinitis treatment patterns and estimate the budgetary impact of a novel rhinitis therapy. METHODS: We developed a three-year budget-ary impact model of rhinitis using Markov-modeling techniques. Transitions between treatment regimens (monotherapy, dualcombination therapy, tri-combination therapy), treatment patterns, (therapy switching, add-on rates), and associated medicalcare costs, were estimated from a large claims database, by identifying rhinitis patients and tracking changes in therapy over time. Budgetary impact of a novel treatment was assessed for three effectiveness scenarios, where the switching/add-on rates relative to fluticasone propionate, an existing rhinitis therapy, were 50% lower (Scenario 1), 25% lower (Scenario 2) and identical (Scenario 3). The novel treatment was assumed to be priced the same as fluticasone propionate and have a market share of 10%. RESULTS: The claims analysis found annual rates of treatment switching, add-on, and remaining on initial therapy ranging from 6-18%, 20-28%, and 62-72%, respectively, for currently existing rhinitis therapies. Annual rhinitis-related medical costs associated with each treatment pattern were $666, $657, and $558, respectively. In Scenario 1, the model predicted the per-patient-per-month (PPPM) budgetary impact for the novel treatment to be -$0.06, -$0.09, and -$0.11, in years 1-3, respectively. Scenarios 2 and 3 had corresponding PPPM results of $0.00, -$0.01, and -$0.01, and $0.05, $0.06, $0.08. CON-CLUSION: Using claims data and Markov-modeling techniques, we found that budgetary impact can be materially affected by rates of treatment switching/add-on. Detailed, claims-based data are required for this type of analysis, given the real-world nature of treatment patterns and associated medical costs.
PAA19

BI-MODALITY IN DISTRIBUTION OF MEDICATION POSSESSION RATIOS FOR ASTHMA CONTROLLER THERAPIES
Langley P 1 , Wagner S 2 1 University of Minnesota, Minneapolis, MN, USA, 2 AstraZeneca, Wilmington, DE, USA OBJECTIVES: We hypothesized that the average medication possession ratio (MPR) for controller medications in adult asthmatic populations may be misleading as a basis for evaluating adherence. METHODS: MPR distributions were determined from analysis of the Pharmetrics database for the period April 2004 to March 2005. We assessed MPRs for those plan members exclusively on one of the three major controller medication groups: inhaled corticosteroids, combined inhaled corticosteroids and long acting beta agonists, and leukotriene modifiers. MPR were defined in terms of annual days supplied (range 0 to 1.0). RESULTS: Overall, for the study population (n = 17,581) 5,806 were exclusively on combination therapy (33.8%), 2,689 were exclusively on leukotriene modifiers (15.3%) and 2,106 exclusively on inhaled corticosteroids (12.0%). Average (median) MPRs were 0.51 (0.57) for combination therapy; 0.55 (0.63) for leukotriene modifiers; and 0.39 (0.33) for inhaled corticosteroids. Distributions of MPRs for these groups showed significant bi-modality (a "U" shaped MPR profile). This characteristic was most pronounced for the combined controller group medications and the leukotriene modifiers where the frequency distributions were almost identical. For the combined medications 32.2% of adults reported a MPR < 0.2, with 19.0% and 28.9% reporting MPRs of 0.6 to 0.79 and 0.8 to 1.0 respectively. The corresponding estimates for leukotriene modifiers were 27.5%, 19.6% and 33.1% respectively. For inhaled corticosteroids, 45.2% of patients reported an MPR < 0.2 with only 33.2% reporting an MPR > 0.6 (15.5% > 0.8). CONCLUSION: This analysis confirms the hypothesis that average MPR may be a misleading indicator of adherence in patients taking combined controller medications and leukotriene modifiers. We suggest an approach
